Investors Research Corp’s Novo Nordisk NVO Stock Holding History

Investors Research Corp’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$874K	Sell	18,225 -250	-1%	-$10.7K	0.16%	111
2026 Q1	$679K	Buy	+18,475	New	+$875K	0.13%	141
2023 Q1	–	Sell	-64	Closed	-$4.33K	–	1148
2022 Q4	$4.33K	Sell	64 -68	-52%	-$3.99K	﹤0.01%	893
2022 Q3	$7K	Buy	132 +64	+94%	+$3.43K	﹤0.01%	810
2022 Q2	$4K	Buy	+68	New	+$3.77K	﹤0.01%	880
2020 Q2	–	Sell	-17,060	Closed	-$514K	–	1111
2020 Q1	$514K	Sell	17,060 -400	-2%	-$11.9K	0.32%	102
2019 Q4	$505K	Hold	17,460	–	–	0.23%	147
2019 Q3	$451K	Hold	17,460	–	–	0.23%	145
2019 Q2	$446K	Hold	17,460	–	–	0.23%	141
2019 Q1	$457K	Hold	17,460	–	–	0.24%	138
2018 Q4	$402K	Hold	17,460	–	–	0.28%	142
2018 Q3	$412K	Sell	17,460 -600	-3%	-$14.6K	0.24%	168
2018 Q2	$416K	Buy	18,060 +60	+0.3%	+$1.43K	0.24%	163
2018 Q1	$443K	Hold	18,000	–	–	0.27%	147
2017 Q4	$483K	Buy	+18,000	New	+$458K	0.3%	126

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Investors Research Corp's NVO Position: Q2 2026 in Review

Investors Research Corp reduced its Novo Nordisk (NVO) stake by 1.4% in Q2 2026, selling an estimated $10.7K and leaving 18,225 shares worth $874K. The position accounts for 0.16% of the portfolio, ranked #111.

Investors Research Corp first reported a position in NVO in Q4 2017 and has held it in 15 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Investors Research Corp held 18,225 shares of Novo Nordisk worth $874K as of Q2 2026.
Investors Research Corp sold 250 Novo Nordisk shares in Q2 2026, an estimated $10.7K.
Novo Nordisk made up 0.16% of Investors Research Corp's portfolio in Q2 2026, its #111 holding.
Investors Research Corp first reported a position in Novo Nordisk in Q4 2017 and has held it in 15 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.